Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
Returns on capital
Erasca, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.3%
avg -29.7%
ROIC
-35.3%
avg -44.6%
ROA
-31.4%
avg -38.6%
Analysis
ROA is currently the strongest return metric at -31.4% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | USD 1.16M | 54 | 2.00M | 0.64% |
David Chacko | Chief Financial Officer & Chief Business Officer | USD 775.22K | 43 | — | — |
Shannon Morris | Chief Medical Officer | USD 772.7K | 56 | 0 | <0.01% |
Ebun S. Garner | Chief Legal Officer & Corporate Secretary | USD 607.44K | 54 | — | — |
Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | USD 93.18K | 68 | — | — |
Lisa Tesvich-Bonora | Chief People Officer | — | — | — | — |
Nicholas Chetwyn | Chief Operating Officer | — | — | — | — |
Brian L. Baker | Senior Vice President of Finance | — | 59 | — | — |
Chandra D. Lovejoy | Chief Regulatory Affairs Officer | — | 55 | — | — |
Robert Shoemaker | Chief Scientific Officer | — | 45 | — | — |
Alison Tjosvold Milhous | Senior Vice President of Accounting | — | 47 | — | — |
Nik Chetwyn | Chief Operating Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 4, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$2.28M
Net Transaction Value
−$2.28M
Net selling
Most Active
Garner Ebun
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 1, 26Apr 1, 2026 | Garner Ebun Direct | Sell | $1.3M$1,312,000.00 |
| Mar 4, 26Mar 4, 2026 | Morris Shannon Direct | Sell | $300.8K$300,760.00 |
| Jan 7, 26Jan 7, 2026 | Garner Ebun Direct | Sell | $670.8K$670,812.00 |
Summary
Insiders reported 0 buys worth $0.00 and 3 sells worth $2.28M over the last 12 months. That adds up to net selling of $2.28M. Garner Ebun was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Erasca, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ERAS's management, answered from reported figures.
Who manages ERAS?
Erasca, Inc. (ERAS) lists 12 active executives. The top listed executive is Lisa Tesvich-Bonora, Chief People Officer.
Are ERAS insiders buying or selling?
Recent insider activity shows net buying of $142.28M.
Continue the stock analysis
Jump to another research area for this company.